Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

NCT03692767 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory B-Cell Lymphoma

Interventions

BIOLOGICAL: Anti-CD22 CAR NK Cells

Sponsor

Allife Medical Science and Technology Co., Ltd.